ChemAxon Announces new CEO and Head of R&D
News May 13, 2008
ChemAxon, a software solutions provider for cheminformatics, has announced the appointment of Alex Drijver as CEO. The arrival signals the companies increased focus on business development and market position.
Ferenc Csizmadia, founder and former CEO, moves to Chairman and Head of Research and Development. The new R&D position formalizes the bridge between the customer base and the company’s development strategy and in particular the next generation of products under launch.
Alex joins ChemAxon with over 20 years international commercial experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest based manufacturer of novel microfluidic based instruments for chemical synthesis, and CFO of ComGenex, Inc., a chemistry services provider now part of Albany Molecular.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019